Il y a eu 50 transactions d'initiés récentes enregistrées pour Oramed Pharmaceuticals Inc. (ORMP), dont 40 achats et 6 ventes. Le total des achats d'initiés s'élève à $1.44K et le total des ventes d'initiés à $1.59M.
Les initiés notables ayant une activité récente comprennent Kidron Nadav, Kidron Miriam, Hexter Joshua. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — ORMP
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-03-30 |
Kidron Nadav |
President and CEO |
Retenue Fiscale RSU |
44,818 |
$3.31 |
$148.35K |
3,422,243 |
| 2026-03-30 |
Kidron Miriam |
Chief Scientific Officer |
Retenue Fiscale RSU |
435,084 |
$3.31 |
$1.44M |
1,133,138 |
| 2026-03-17 |
Kidron Nadav |
President and CEO |
Attribution de RSU |
167,005 |
- |
- |
3,422,243 |
| 2026-03-17 |
Kidron Miriam |
Chief Scientific Officer |
Attribution de RSU |
119,558 |
- |
- |
1,568,222 |
| 2026-03-17 |
Hexter Joshua |
COO & Cbo |
Attribution de RSU |
95,889 |
- |
- |
1,160,384 |
| 2026-03-17 |
Gabay Avraham |
Chief Financial Officer |
Attribution de RSU |
95,889 |
- |
- |
745,145 |
| 2026-03-12 |
Kidron Nadav |
President and CEO |
Don (Donné) |
100,000 |
- |
- |
3,255,238 |
| 2026-01-22 |
Kidron Nadav |
President and CEO |
Exercice d'Options (Vente) |
109,000 |
- |
- |
- |
| 2026-01-22 |
Kidron Miriam |
Chief Scientific Officer |
Exercice d'Options (Vente) |
19,000 |
- |
- |
- |
| 2026-01-22 |
Hexter Joshua |
COO & Cbo |
Exercice d'Options (Vente) |
19,000 |
- |
- |
- |
| 2026-01-22 |
Gabay Avraham |
Chief Financial Officer |
Exercice d'Options (Vente) |
19,000 |
- |
- |
- |
| 2026-01-14 |
Kidron Miriam |
Chief Scientific Officer |
Don (Donné) |
86,166 |
- |
- |
1,343,498 |
| 2025-12-31 |
Gabay Avraham |
Chief Financial Officer |
Attribution de RSU |
19,000 |
- |
- |
19,000 |
| 2025-12-31 |
Aghion Daniel |
Director |
Attribution de RSU |
30,000 |
$0.01 |
$360.00 |
107,191 |
| 2025-12-31 |
Kidron Nadav |
President and CEO |
Attribution de RSU |
109,000 |
- |
- |
109,000 |
| 2025-12-31 |
Kidron Miriam |
Chief Scientific Officer |
Attribution de RSU |
19,000 |
- |
- |
19,000 |
| 2025-12-31 |
Hexter Joshua |
COO & Cbo |
Attribution de RSU |
19,000 |
- |
- |
19,000 |
| 2025-12-31 |
Mayer Arie |
Director |
Attribution de RSU |
30,000 |
$0.01 |
$360.00 |
163,109 |
| 2025-12-31 |
Shapiro Benjamin |
Director |
Attribution de RSU |
30,000 |
$0.01 |
$360.00 |
119,720 |
| 2025-12-31 |
Reznick Yehuda |
Director |
Attribution de RSU |
30,000 |
$0.01 |
$360.00 |
98,930 |
| 2025-06-05 |
Sank Leonard |
Director |
Attribution de RSU |
30,000 |
- |
- |
128,021 |
| 2025-06-05 |
Mayer Arie |
Director |
Attribution de RSU |
30,000 |
- |
- |
126,134 |
| 2025-06-05 |
Shapiro Benjamin |
Director |
Attribution de RSU |
30,000 |
- |
- |
85,070 |
| 2025-06-05 |
Aghion Daniel |
Director |
Attribution de RSU |
30,000 |
- |
- |
68,820 |
| 2025-06-05 |
Reznick Yehuda |
Director |
Attribution de RSU |
30,000 |
- |
- |
60,560 |
| 2025-02-11 |
Kidron Nadav |
President and CEO |
Attribution de RSU |
141,000 |
- |
- |
2,400,598 |
| 2025-02-11 |
Kidron Miriam |
Chief Scientific Officer |
Attribution de RSU |
74,000 |
- |
- |
1,074,666 |
| 2025-02-11 |
Hexter Joshua |
COO & Cbo |
Attribution de RSU |
45,000 |
- |
- |
751,333 |
| 2025-02-11 |
Gabay Avraham |
Chief Financial Officer |
Attribution de RSU |
34,000 |
- |
- |
392,040 |
| 2025-01-02 |
Kidron Nadav |
President and CEO |
Attribution de RSU |
433,500 |
- |
- |
2,259,598 |
| 2025-01-02 |
Kidron Miriam |
Chief Scientific Officer |
Attribution de RSU |
207,000 |
- |
- |
1,000,666 |
| 2025-01-02 |
Hexter Joshua |
COO & Cbo |
Attribution de RSU |
194,500 |
- |
- |
706,333 |
| 2025-01-02 |
Gabay Avraham |
Chief Financial Officer |
Attribution de RSU |
188,000 |
- |
- |
358,040 |
| 2024-11-07 |
Kidron Nadav |
President and CEO |
Attribution de RSU |
45,000 |
- |
- |
1,826,098 |
| 2024-11-07 |
Kidron Miriam |
Chief Scientific Officer |
Attribution de RSU |
30,000 |
- |
- |
793,666 |
| 2024-11-07 |
Hexter Joshua |
COO & Cbo |
Attribution de RSU |
30,000 |
- |
- |
511,833 |
| 2024-11-07 |
Gabay Avraham |
Chief Financial Officer |
Attribution de RSU |
30,000 |
- |
- |
170,040 |
| 2024-06-21 |
Gabay Avraham |
Chief Financial Officer |
Attribution de RSU |
140,040 |
- |
- |
- |
| 2024-06-18 |
Gabay Avraham |
Officer |
Inconnu |
- |
- |
- |
- |
| 2024-06-06 |
Reznick Yehuda |
Director |
Attribution de RSU |
760 |
- |
- |
30,560 |
| 2024-04-17 |
Reznick Yehuda |
Director |
Attribution de RSU |
29,800 |
- |
- |
29,800 |
| 2024-04-01 |
Reznick Yehuda |
Director |
Inconnu |
- |
- |
- |
- |
| 2024-01-30 |
Aghion Daniel |
Director |
Attribution de RSU |
3,750 |
- |
- |
38,820 |
| 2024-01-04 |
Kidron Nadav |
President and CEO |
Attribution de RSU |
329,000 |
- |
- |
1,781,098 |
| 2024-01-04 |
Kidron Miriam |
Chief Scientific Officer |
Attribution de RSU |
295,500 |
- |
- |
763,666 |
| 2024-01-04 |
Sank Leonard |
Director |
Attribution de RSU |
30,000 |
- |
- |
88,696 |
| 2024-01-04 |
Hexter Joshua |
COO & Cbo |
Attribution de RSU |
180,500 |
- |
- |
481,833 |
| 2024-01-04 |
Mayer Arie |
Director |
Attribution de RSU |
30,000 |
- |
- |
86,809 |
| 2024-01-04 |
Silberman David |
Chief Financial Officer |
Attribution de RSU |
136,500 |
- |
- |
366,500 |
| 2024-01-04 |
Rozov Yadin |
Director |
Attribution de RSU |
30,000 |
- |
- |
146,500 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi